Patents Assigned to OncoNOx APS
  • Patent number: 9777057
    Abstract: Human recombinant antibodies or fragments thereof having specificity for the ?2-glycoprotein I (?2GPI), pharmaceutical compositions containing same and use thereof in a method for treating or preventing thrombus formation and fetal loss in a patient affected by antiphospholipid syndrome (APS).
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: October 3, 2017
    Assignee: ONCONOX APS
    Inventors: Francesco Tedesco, Pier Luigi Meroni, Daniele Sblattero
  • Publication number: 20160152696
    Abstract: Human recombinant antibodies or fragments thereof having specificity for the ?2-glycoprotein I (?2GPI), pharmaceutical compositions containing same and use thereof in a method for treating or preventing thrombus formation and fetal loss in a patient affected by antiphospholipid syndrome (APS).
    Type: Application
    Filed: July 7, 2014
    Publication date: June 2, 2016
    Applicant: ONCONOX APS
    Inventors: Francesco TEDESCO, Pier Luigi MORONI, Daniele SBLATTERO
  • Patent number: 8563578
    Abstract: HIV-protease inhibitors, particularly saquinavir, showed strong anticancer activity but numerous side effects limited its application. In order to overcome its toxicity original compounds were modified by covalent attachment of NO. The efficacy of parental and NO-modified drug was compared in vitro and in vivo. Anticancer activities of NO-modified saquinavir (Saq-NO) was monitored in vitro using assay for cell viability, proliferation, necrotic, autophagic and apoptotic cell death, differentiation, expression of intracellular molecules such as cyclin D3, p53 and Akt. Antitumor properties and toxicity of the compound was estimated in vivo. Saq-NO abrogated the viability of large spectrum of human and rodent tumor cell lines with IC50 significantly lower than parental drug and expressed strong antimelanoma action in vivo. In contrast to saquinavir, there was no detectable toxicity against primary cells in vitro and in vivo.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: October 22, 2013
    Assignee: Onconox APS
    Inventors: Ferdinando Nicoletti, Yousef Al-Abed, Gianni Garotta
  • Patent number: 8207206
    Abstract: The present invention relates to an isoxazole derivative, the compound of formula (I) herein after referred to as GIT27-NO, which is the NO-donating structurally modified form of (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid, herein after referred to as VGX-1027. Treatment of three tumor cell lines, rat astrocytoma C6, mouse fibrosarcoma L929, and mouse melanoma B16 cells with GIT27-NO resulted in a significant reduction of cell respiration and of number of viable cells, while VGX-1027 was completely ineffective. Hemoglobin, which act as NO-scavenger, restored cell viability, thus indicating the NO-mediated tumoricidal effect of compound (I). GIT27-NO triggered apoptotic cell death in L929 cell cultures, while autophagic cell death is mainly responsible for the diminished viability of C6 and B16 cells.
    Type: Grant
    Filed: May 6, 2008
    Date of Patent: June 26, 2012
    Assignee: OncoNOx APS
    Inventors: Ferdinando Nicoletti, Yousef Al-Abed, Gianni Garotta